TopoTarget and Lundbeck Sign Agreement for Siramesine

TopoTarget A/S and Lundbeck A/S have announced an agreement for the development of siramesine for the treatment of cancer. Siramesine has shown strong results in preclinical studies carried out by the Danish Cancer Society. The studies showed that siramesine kills cancer cells via a new and promising mechanism. Siramesine was originally developed by Lundbeck for the treatment of diseases of the central nervous system, and TopoTarget now intends to initiate studies with the compound in cancer therapy.

Applying its special expertise and in-house discovery models, TopoTarget seeks to identify the best Phase II development opportunities for the benefit of cancer patients. The successful completion of Phase II may lead to yet another partner entering the collaboration with a view to further clinical and commercial development. Any future income will be evenly divided between TopoTarget and Lundbeck.

Siramesine binds to a special sub-type of sigma receptor, A 2. Siramesine has previously been investigated in Phase I and Phase IIa studies as a CNS-active compound for the treatment of anxiety, demonstrating a favourable tolerability profile.

Novel studies conducted under the supervision of professor Marja Jäättelä of the Danish Cancer Society showed that siramesine induces caspase independent apoptosis in cancer cells and is effective in preclinical cancer models, both as monotherapy and in combination with currently marketed anti-cancer drugs.

For further information please contact:

Peter Buhl Jensen,

CEO

Tel: +45 39 17 83 41

Email: pbj@topotarget.com